Статті в журналах з теми "Oral P2Y12 inhibitor"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся з топ-50 статей у журналах для дослідження на тему "Oral P2Y12 inhibitor".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.
Prüller, Florian, Lukasz Bis, Oliver Milke, Friedrich Fruhwald, Sascha Pätzold, Siegfried Altmanninger-Sock, Jolanta Siller-Matula, et al. "Cangrelor Induces More Potent Platelet Inhibition without Increasing Bleeding in Resuscitated Patients." Journal of Clinical Medicine 7, no. 11 (November 15, 2018): 442. http://dx.doi.org/10.3390/jcm7110442.
Повний текст джерелаAlexopoulos, Dimitrios, Stylianos Dragasis, and Nikolaos Kafkas. "Loading with Oral P2Y12 Receptor Inhibitors: To Crush or Not to Crush?" Thrombosis and Haemostasis 119, no. 07 (May 12, 2019): 1037–47. http://dx.doi.org/10.1055/s-0039-1688790.
Повний текст джерелаStratz, Christian, Thomas Nührenberg, Christian Valina, Nikolaus Löffelhardt, Kambis Mashayekhi, Miroslaw Ferenc, Dietmar Trenk, Franz-Josef Neumann, and Willibald Hochholzer. "Impact of Reticulated Platelets on the Antiplatelet Effect of the Intravenous P2Y12-Receptor Inhibitor Cangrelor." Thrombosis and Haemostasis 118, no. 02 (2018): 362–68. http://dx.doi.org/10.1160/th17-07-0466.
Повний текст джерелаZhou, Xuan, Dominick J. Angiolillo, and Luis Ortega-Paz. "P2Y12 Inhibitor Monotherapy after Percutaneous Coronary Intervention." Journal of Cardiovascular Development and Disease 9, no. 10 (October 6, 2022): 340. http://dx.doi.org/10.3390/jcdd9100340.
Повний текст джерелаDroppa, Michal, Oliver Borst, Dominik Rath, Karin Müller, Meinrad Gawaz, Deepak L. Bhatt, and Tobia Geisler. "Impact of Intravenous P2Y12-Receptor Inhibition with Cangrelor in Patients Presenting with Acute Coronary Syndrome and Cardiogenic Shock – a Case Series." Cellular Physiology and Biochemistry 42, no. 4 (2017): 1336–41. http://dx.doi.org/10.1159/000478962.
Повний текст джерелаMenozzi, Alberto, and Giorgio Caretta. "Acute coronary syndromes with high thrombotic burden: therapeutic innovations." European Heart Journal Supplements 22, Supplement_L (November 1, 2020): L97—L100. http://dx.doi.org/10.1093/eurheartj/suaa144.
Повний текст джерелаJhagroe, Darshni Arishta, and Jurriën Maria ten Berg. "Managing the Antithrombotic Therapy After Percutaneous Coronary Intervention in Patients on Oral Anticoagulation." Interventional Cardiology Review 10, no. 3 (2015): 139. http://dx.doi.org/10.15420/icr.2015.10.03.139.
Повний текст джерелаVlachou, Maria, Matthaios Didagelos, Antonios Kouparanis, Haralambos Karvounis, and Antonios Ziakas. "Bridging with Tirofiban During Temporary Withdrawal of Oral Antiplatelets for Two Major Surgical Procedures in High Ischaemic Risk Patients." Open Cardiovascular Medicine Journal 13, no. 1 (February 15, 2019): 1–4. http://dx.doi.org/10.2174/1874192401913010001.
Повний текст джерелаChua, Su-Kiat, Lung-Ching Chen, Kou-Gi Shyu, Jun-Jack Cheng, Huei-Fong Hung, Chiung-Zuan Chiu, and Chiu-Mei Lin. "Antithrombotic Strategies in Patients with Atrial Fibrillation Following Percutaneous Coronary Intervention: A Systemic Review and Network Meta-Analysis of Randomized Controlled Trials." Journal of Clinical Medicine 9, no. 4 (April 8, 2020): 1062. http://dx.doi.org/10.3390/jcm9041062.
Повний текст джерелаLupercio, Florentino, Shaun Giancaterino, Pedro Arturo Villablanca, Frederick Han, Kurt Hoffmayer, Gordon Ho, Farshad Raissi, et al. "P2Y12 inhibitors with oral anticoagulation for percutaneous coronary intervention with atrial fibrillation: a systematic review and meta-analysis." Heart 106, no. 8 (February 7, 2020): 575–83. http://dx.doi.org/10.1136/heartjnl-2019-315963.
Повний текст джерелаCohen, Michael V., and James M. Downey. "What Are Optimal P2Y12 Inhibitor and Schedule of Administration in Patients With Acute Coronary Syndrome?" Journal of Cardiovascular Pharmacology and Therapeutics 25, no. 2 (October 23, 2019): 121–30. http://dx.doi.org/10.1177/1074248419882923.
Повний текст джерелаPereira, Naveen L., Charanjit Rihal, Ryan Lennon, Gil Marcus, Sanskriti Shrivastava, Malcolm R. Bell, Derek So, et al. "Effect of CYP2C19 Genotype on Ischemic Outcomes During Oral P2Y12 Inhibitor Therapy." JACC: Cardiovascular Interventions 14, no. 7 (April 2021): 739–50. http://dx.doi.org/10.1016/j.jcin.2021.01.024.
Повний текст джерелаPanov, A. V. "Antithrombotic Management for Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention." Rational Pharmacotherapy in Cardiology 17, no. 4 (September 3, 2021): 628–37. http://dx.doi.org/10.20996/1819-6446-2021-07-02.
Повний текст джерелаSerebruany, Victor L., Vasily Cherepanov, Moo Hyun Kim, Oleg Litvinov, Hector A. Cabrera-Fuentes, and Thomas A. Marciniak. "Filing Sources after Oral P2Y12 Platelet Inhibitors to the Food and Drug Administration Adverse Event Reporting System (FAERS)." Cardiology 138, no. 4 (2017): 249–53. http://dx.doi.org/10.1159/000479786.
Повний текст джерелаIbrahim, Khalil, Rohan Shah, Rakesh Goli, Thomas Kickler, William Clarke, Rani Hasan, Roger Blumenthal, et al. "Fentanyl Delays the Platelet Inhibition Effects of Oral Ticagrelor: Full Report of the PACIFY Randomized Clinical Trial." Thrombosis and Haemostasis 118, no. 08 (July 4, 2018): 1409–18. http://dx.doi.org/10.1055/s-0038-1666862.
Повний текст джерелаMainka, Felipe F., Vinicius L. Ferreira, Antonio M. Mendes, Gustavo L. Marques, Fernando Fernandez-Llimos, Fernanda S. Tonin, and Roberto Pontarolo. "Safety and Efficacy of Oral Anticoagulants Therapies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Network Meta-Analysis." Journal of Cardiovascular Pharmacology and Therapeutics 25, no. 5 (June 3, 2020): 399–408. http://dx.doi.org/10.1177/1074248420930136.
Повний текст джерелаHochholzer, Willibald, Pascal Kleiner, Iris Younas, Christian M. Valina, Nikolaus Löffelhardt, Michael Amann, Timo Bömicke, et al. "Randomized Comparison of Oral P2Y12-Receptor Inhibitor Loading Strategies for Transitioning From Cangrelor." JACC: Cardiovascular Interventions 10, no. 2 (January 2017): 121–29. http://dx.doi.org/10.1016/j.jcin.2016.10.004.
Повний текст джерелаSotomi, Yohei, Ken Kozuma, Kosuke Kashiwabara, Yoshiharu Higuchi, Kenji Ando, Yoshihiro Morino, Junya Ako, et al. "Randomised controlled trial to investigate optimal antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: a study protocol of the OPTIMA-AF trial." BMJ Open 11, no. 12 (December 2021): e048354. http://dx.doi.org/10.1136/bmjopen-2020-048354.
Повний текст джерелаKomosa, Anna, Maciej Lesiak, Zbigniew Krasiński, Marek Grygier, Andrzej Siniawski, Włodzimierz Skorupski, Anna Olasińska-Wiśniewska, et al. "Optimal Timing of P2Y12 Inhibitor Loading in Patients Undergoing PCI: A Meta-Analysis." Thrombosis and Haemostasis 119, no. 06 (March 27, 2019): 1000–1020. http://dx.doi.org/10.1055/s-0039-1683421.
Повний текст джерелаRatcovich, Hanna, Luigi Biasco, Frants Pedersen, Steffen Helqvist, Kari Saunamaki, Hans-Henrik Tilsted, Peter Clemmensen, et al. "Prehospital administration of P2Y12 inhibitors and early coronary reperfusion in primary PCI: an observational comparative study." Thrombosis and Haemostasis 114, no. 09 (2015): 623–31. http://dx.doi.org/10.1160/th15-01-0026.
Повний текст джерелаGalli, Mattia, Stefano Benenati, Francesco Franchi, Fabiana Rollini, Davide Capodanno, Giuseppe Biondi-Zoccai, Giovanni Maria Vescovo, et al. "Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials." European Heart Journal 43, no. 10 (December 16, 2021): 959–67. http://dx.doi.org/10.1093/eurheartj/ehab836.
Повний текст джерелаWang, Yanhua, Yueping Sun, Ding Li, Lin Zhang, Kemin Wang, Weiran Chai, Xinping Luo, T. Kent Gartner, and Junling Liu. "P2Y12 Is Involved in Cancer Metastasis,." Blood 118, no. 21 (November 18, 2011): 3356. http://dx.doi.org/10.1182/blood.v118.21.3356.3356.
Повний текст джерелаFarooq, Muhammad Zain, Prasanth Lingamaneni, Muhammad Saad Farooq, Aakash Putta, Sheeba Ba Aqeel, VV Pavan Kedar Mukthinuthalapati, Ankit Mangla, and Paul Rubinstein. "Comparison of New Oral Anticoagulants (NOAC) Based Double Therapy Versus Vitamin K Antagonist Based Triple Therapy in Patients Undergoing Percutaneous Coronary Intervention with Atrial Fibrillation: A Systematic Review and Meta-Analysis." Blood 134, Supplement_1 (November 13, 2019): 4963. http://dx.doi.org/10.1182/blood-2019-129607.
Повний текст джерелаKatz, Moshe, Ehud Regev, Avi Sabbag, Israel Mazin, Arsalan Abu-Much, Andrew Kukuy, Anna Mazo, et al. "Chewing versus Swallowing Ticagrelor to Accelerate Platelet Inhibition in Acute Coronary Syndrome - the CHEERS study." Thrombosis and Haemostasis 117, no. 04 (2017): 727–33. http://dx.doi.org/10.1160/th16-09-0728.
Повний текст джерелаErlich, A. D. "Possibility of using dabigatran in patients with atrial fibrillation and acute coronary syndrome and PCI." Medical Council, no. 5 (April 4, 2019): 30–35. http://dx.doi.org/10.21518/2079-701x-2019-5-30-35.
Повний текст джерелаSukhinina, T. S., D. V. Pevzner, A. V. Mazurov, T. N. Vlasik, N. G. Solovieva, N. S. Kostritca, R. M. Shakhnovich, and I. S. Yavelov. "The role of platelet glycoprotein IIb / IIIa inhibitors in current treatment of acute coronary syndrome." Kardiologiia 62, no. 4 (April 30, 2022): 64–72. http://dx.doi.org/10.18087/cardio.2022.4.n2020.
Повний текст джерелаBrand, Aarent RT, Eline Houben, Irene D. Bezemer, Frank L. J. Visseren, Michiel L. Bots, Ron MC Herings, and Gert-Jan de Borst. "Platelet aggregation inhibitor prescription for newly diagnosed peripheral arterial disease in the Netherlands: a cohort study." BMJ Open 11, no. 1 (January 2021): e041715. http://dx.doi.org/10.1136/bmjopen-2020-041715.
Повний текст джерелаRashid, Khalid, Muhammad Aamir Waheed, Hafeez Ur Rehman, and Abdel-Naser Elzouki. "Severe diarrhoea due to use of P2Y12 inhibitor ticagrelor: a rarely reported adverse event." BMJ Case Reports 14, no. 7 (July 2021): e242199. http://dx.doi.org/10.1136/bcr-2021-242199.
Повний текст джерелаMori, Hiroyoshi, Takuya Mizukami, Atsuo Maeda, Kazuki Fukui, Yoshihiro Akashi, Junya Ako, Yuji Ikari, et al. "A Japanese Dose of Prasugrel versus a Standard Dose of Clopidogrel in Patients with Acute Myocardial Infarction from the K-ACTIVE Registry." Journal of Clinical Medicine 11, no. 7 (April 4, 2022): 2016. http://dx.doi.org/10.3390/jcm11072016.
Повний текст джерелаBor, Wilbert, and Diana A. Gorog. "Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndrome." Journal of Clinical Medicine 9, no. 7 (June 27, 2020): 2020. http://dx.doi.org/10.3390/jcm9072020.
Повний текст джерелаAlexopoulos, Dimitrios, Christos Pappas, Danai Sfantou, and John Lekakis. "Cangrelor in Percutaneous Coronary Intervention: Current Status and Perspectives." Journal of Cardiovascular Pharmacology and Therapeutics 23, no. 1 (June 15, 2017): 13–22. http://dx.doi.org/10.1177/1074248417715004.
Повний текст джерелаAbraham, Neena S., Alan N. Barkun, Bryan G. Sauer, James Douketis, Loren Laine, Peter A. Noseworthy, Jennifer J. Telford, and Grigorios I. Leontiadis. "American College of Gastroenterology-Canadian Association of Gastroenterology Clinical Practice Guideline: Management of Anticoagulants and Antiplatelets During Acute Gastrointestinal Bleeding and the Periendoscopic Period." Journal of the Canadian Association of Gastroenterology 5, no. 2 (March 17, 2022): 100–101. http://dx.doi.org/10.1093/jcag/gwac010.
Повний текст джерелаCarrillo-Aleman, Luna, Francisco Marín, José M. Rivera-Caravaca, Nuria Vicente-Ibarra, Elena Candela-Sanchez, Maria A. Esteve-Pastor, Teresa Lozano, et al. "Switching of Oral P2Y12 Inhibitor Treatment in Patients with Acute Coronary Syndrome: Prevalence, Predictors, and Prognosis." Clinical Drug Investigation 39, no. 3 (January 8, 2019): 275–83. http://dx.doi.org/10.1007/s40261-018-0736-z.
Повний текст джерелаTarantini, Giuseppe, Marco Mojoli, Ferdinando Varbella, Roberto Caporale, Stefano Rigattieri, Giuseppe Andò, Plinio Cirillo, et al. "Timing of Oral P2Y12 Inhibitor Administration in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome." Journal of the American College of Cardiology 76, no. 21 (November 2020): 2450–59. http://dx.doi.org/10.1016/j.jacc.2020.08.053.
Повний текст джерелаVerlinden, Nathan J., James C. Coons, Carlo J. Iasella, and Sandra L. Kane-Gill. "Triple Antithrombotic Therapy With Aspirin, P2Y12 Inhibitor, and Warfarin After Percutaneous Coronary Intervention." Journal of Cardiovascular Pharmacology and Therapeutics 22, no. 6 (March 9, 2017): 546–51. http://dx.doi.org/10.1177/1074248417698042.
Повний текст джерелаEindhoven, Daniëlle C., Alexander D. Hilt, Thomas C. Zwaan, Martin J. Schalij, and C. Jan Willem Borleffs. "Age and gender differences in medical adherence after myocardial infarction: Women do not receive optimal treatment – The Netherlands claims database." European Journal of Preventive Cardiology 25, no. 2 (November 22, 2017): 181–89. http://dx.doi.org/10.1177/2047487317744363.
Повний текст джерелаChen, Keyong. "Novel Oral P2Y12 Inhibitor Prasugrel vs. Clopidogrel in Patients with Acute Coronary Syndrome: Evidence Based on 6 Studies." Medical Science Monitor 21 (2015): 1131–37. http://dx.doi.org/10.12659/msm.893914.
Повний текст джерелаSaad, Marwan, Jared Tobolski, Dhaval Kolte, Yongfei Wang, Karl Minges, Ravi S. Hira, Jeptha P. Curtis, and Jinnette Dawn Abbott. "Duration of P2Y12 inhibitor Prescription After Percutaneous Coronary Intervention in Patients on Oral Anticoagulants (from NCDR CathPCI Registry)." American Journal of Cardiology 133 (October 2020): 182–84. http://dx.doi.org/10.1016/j.amjcard.2020.07.029.
Повний текст джерелаvan der Sangen, Niels M. R., Ho Yee Cheung, Niels J. W. Verouden, Yolande Appelman, Marcel A. M. Beijk, Bimmer E. P. M. Claessen, Ronak Delewi, et al. "Cangrelor Use in Routine Practice: A Two-Center Experience." Journal of Clinical Medicine 10, no. 13 (June 26, 2021): 2829. http://dx.doi.org/10.3390/jcm10132829.
Повний текст джерелаPereira, Naveen L., Michael E. Farkouh, Derek So, Ryan Lennon, Nancy Geller, Verghese Mathew, Malcolm Bell, et al. "Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention." JAMA 324, no. 8 (August 25, 2020): 761. http://dx.doi.org/10.1001/jama.2020.12443.
Повний текст джерелаKitahara, Hideki, Kazuya Tateishi, Yuki Shiko, Yusuke Inaba, Yoshio Kobayashi, and Takahiro Inoue. "Comparison of short-term clinical outcomes between low-dose prasugrel and clopidogrel as part of triple antithrombotic therapy in patients requiring oral anticoagulant therapy and percutaneous coronary intervention." PLOS ONE 17, no. 7 (July 28, 2022): e0272140. http://dx.doi.org/10.1371/journal.pone.0272140.
Повний текст джерелаFranchi, Francesco, Fabiana Rollini, Emilio Garcia, Jose Rivas Rios, Andrea Rivas, Malhar Agarwal, Megha Kureti, et al. "Effects of Edoxaban on the Cellular and Protein Phase of Coagulation in Patients with Coronary Artery Disease on Dual Antiplatelet Therapy with Aspirin and Clopidogrel: Results of the EDOX-APT Study." Thrombosis and Haemostasis 120, no. 01 (August 30, 2019): 083–93. http://dx.doi.org/10.1055/s-0039-1695772.
Повний текст джерелаAloia, Elio, Paolo Orselli, and Carlotta Sciaccaluga. "Triple Antithrombotic Therapy vs. Double Antithrombotic Therapy: One Scenario, 8 Questions, Many Conclusions." Current Cardiology Reviews 15, no. 3 (May 6, 2019): 219–23. http://dx.doi.org/10.2174/1573403x15666190111095438.
Повний текст джерелаAltoukhi, Renad M., Reema A. Alshouimi, Shahad M. Al Rammah, Mohammed Y. Alzahrani, Abdulaali R. Almutairi, Abdulmajeed M. Alshehri, Osamah M. Alfayez, Majed S. Al Yami, and Omar A. Almohammed. "Safety and efficacy of dual versus triple antithrombotic therapy (DAT vs TAT) in patients with atrial fibrillation following a PCI: a systematic review and network meta-analysis." BMJ Open 10, no. 9 (September 2020): e036138. http://dx.doi.org/10.1136/bmjopen-2019-036138.
Повний текст джерелаLei, Yu, Bing Zhang, Dan Liu, Jian Zhao, Xiwen Dai, Jun Gao, Qing Mao, et al. "Switching a Xanthine Oxidase Inhibitor to a Dual-Target Antagonist of P2Y1 and P2Y12 as an Oral Antiplatelet Agent with a Wider Therapeutic Window in Rats than Ticagrelor." Journal of Medicinal Chemistry 63, no. 24 (December 12, 2020): 15752–72. http://dx.doi.org/10.1021/acs.jmedchem.0c01524.
Повний текст джерелаKrishnamurthy, Arvindra, Claire Keeble, Michelle Anderson, Kathryn Somers, Natalie Burton-Wood, Charlotte Harland, Paul Baxter, et al. "Real-world comparison of clopidogrel, prasugrel and ticagrelor in patients undergoing primary percutaneous coronary intervention." Open Heart 6, no. 1 (June 2019): e000951. http://dx.doi.org/10.1136/openhrt-2018-000951.
Повний текст джерелаGoette, Andreas, and Pascal Vranckx. "Atrial fibrillation patients undergoing percutaneous coronary intervention: dual or triple antithrombotic therapy with non-vitamin K antagonist oral anticoagulants." European Heart Journal Supplements 22, Supplement_I (September 1, 2020): I22—I31. http://dx.doi.org/10.1093/eurheart/suaa101.
Повний текст джерелаBarańska, Malwina, Adam Sikora, Katarzyna Buszko, Emilia Siemińska, Michał Piotr Marszałł, Jolanta Siller-Matula, Bernd Jilma, et al. "Crushed sublingual versus oral ticagrelor administration strategies in patients with unstable angina." Thrombosis and Haemostasis 117, no. 04 (2017): 718–26. http://dx.doi.org/10.1160/th16-08-0670.
Повний текст джерелаPenna, Claudia, Manuela Aragno, Alessia Sofia Cento, Saveria Femminò, Isabella Russo, Federica Dal Bello, Fausto Chiazza, et al. "Ticagrelor Conditioning Effects Are Not Additive to Cardioprotection Induced by Direct NLRP3 Inflammasome Inhibition: Role of RISK, NLRP3, and Redox Cascades." Oxidative Medicine and Cellular Longevity 2020 (August 4, 2020): 1–12. http://dx.doi.org/10.1155/2020/9219825.
Повний текст джерелаWang, Qiang, and Keping Yang. "Dual therapy with an oral non-vitamin K antagonist and a P2Y12 inhibitor vs triple therapy with aspirin, a P2Y12 inhibitor and a vitamin K antagonist for the treatment of diabetes mellitus patients with co-existing atrial fibrillation following percutaneous coronary intervention." Medicine 100, no. 15 (April 16, 2021): e25546. http://dx.doi.org/10.1097/md.0000000000025546.
Повний текст джерела